Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationEBIATLeasesLoans and Notes ReceivablesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares Outstanding
Ratios

Northwest Biotherapeutics (NWBO) Other Gross PP&E Adjustments (2016 - 2025)

Historic Other Gross PP&E Adjustments for Northwest Biotherapeutics (NWBO) over the last 17 years, with Q3 2025 value amounting to $19.7 million.

  • Northwest Biotherapeutics' Other Gross PP&E Adjustments rose 873.77% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.7 million, marking a year-over-year increase of 873.77%. This contributed to the annual value of $17.6 million for FY2024, which is 360.45% up from last year.
  • As of Q3 2025, Northwest Biotherapeutics' Other Gross PP&E Adjustments stood at $19.7 million, which was up 873.77% from $19.0 million recorded in Q2 2025.
  • In the past 5 years, Northwest Biotherapeutics' Other Gross PP&E Adjustments registered a high of $19.7 million during Q3 2025, and its lowest value of -$5.1 million during Q1 2021.
  • Its 5-year average for Other Gross PP&E Adjustments is $9.6 million, with a median of $16.1 million in 2023.
  • The largest annual percentage gain for Northwest Biotherapeutics' Other Gross PP&E Adjustments in the last 5 years was 51671.0% (2021), contrasted with its biggest fall of 2056.19% (2021).
  • Over the past 5 years, Northwest Biotherapeutics' Other Gross PP&E Adjustments (Quarter) stood at $11.2 million in 2021, then rose by 2.49% to $11.5 million in 2022, then skyrocketed by 47.39% to $17.0 million in 2023, then increased by 3.6% to $17.6 million in 2024, then rose by 12.03% to $19.7 million in 2025.
  • Its last three reported values are $19.7 million in Q3 2025, $19.0 million for Q2 2025, and $18.1 million during Q1 2025.